The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. Even more specifically, the invention relates to the use of cobimetinib and vemurafenib for extending duration of response to treatment, or delaying or preventing development of resistance to treatment, of BRAF V600 mutation-positive unresectable or metastatic melanoma.
